ID: h-05e92f66f1
Hypothesis
CSF p-tau217 Normalization Requires Intact Synaptic Function and BBB Integrity (Neurodegeneration Floor Effect)
In advanced neurodegeneration, p-tau217 may no longer reflect ongoing pathology due to loss of viable neurons capable of producing tau.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
🧪 Overview
In advanced neurodegeneration, p-tau217 may no longer reflect ongoing pathology due to loss of viable neurons capable of producing tau. Patients with severe atrophy may show spurious p-tau217 normalization due to floor effects, making it unreliable as a stopping rule. However, no threshold defines 'severe' neurodegeneration for this purpose, and the relationship between structural atrophy and neuronal p-tau217 production capacity is not established. The hypothesis identifies an important confound but lacks operational criteria.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["MAPT/Tau Protein<br/>Microtubule Stabilizer"]
B["CDK5/GSK3B Activation<br/>Kinase Dysregulation"]
C["Tau Hyperphosphorylation<br/>Ser396/Thr231/Ser202"]
D["Tau Detachment<br/>Microtubule Destabilized"]
E["Tau Oligomers<br/>Paired Helical Filaments"]
F["Neurofibrillary Tangles<br/>Intraneuronal Inclusions"]
G["Axonal Transport Failure<br/>Synaptic Dysfunction"]
H["Neurodegeneration<br/>Tauopathy Spread"]
A --> B
B --> C
C --> D
D --> E
E --> F
D --> G
G --> H
F --> H
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
Neurofilament light trajectories diverge based on baseline atrophy in donanemab trials
Supports
Streamlined resource-efficient plasma amyloid-beta mass spectrometry assay has improved biomarker performance in preclinical Alzheimer's disease.
Contradicts
No published study explicitly tests p-tau217 validity across neurodegeneration severity strata
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NA
No curated PDB or AlphaFold mapping for NA yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NA - Patient stratification factor.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0143
Events (7d)
1
Price History
▲0.7%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF amyloid-targeted immunotherapy is administered to patients with severe cortical atrophy (global cortical thickness <1.5mm) versus preserved cortical thickness (>2.0mm), THEN CSF p-tau217 will decli | Patients with preserved cortical thickness will show ≥30% reduction in CSF p-tau217 at month 12 post-treatment, while severe-atrophy patients will show <10% cha | — no observation — | pending | 0.35 |
| IF CSF p-tau217 levels are used to stratify patients with advanced atrophy (hippocampal volume >2 SD below age-matched controls) versus moderate atrophy, THEN the high-atrophy group will show no signi | Baseline p-tau217 will predict 18-month clinical decline only in the moderate-atrophy cohort, not in the advanced-atrophy cohort, with correlation coefficients | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF CSF p-tau217 levels are used to stratify patients with advanced atrophy (hippocampal volume >2 SD below age-matched controls) versus moderate atrophy, THEN the high-atrophy group will show no significant correlation between baseline p-tau217 and 18-month clinical decline (CDR-SB change ≥1.5), whe
Predicted outcome: Baseline p-tau217 will predict 18-month clinical decline only in the moderate-atrophy cohort, not in the advanced-atrophy cohort, with correlation coe
Falsification: Both atrophy groups show equivalent predictive value of baseline p-tau217 for 18-month clinical decline, with non-significant difference in correlation coefficients (diff<0.2), disproving a floor effe
pendingconf 35%
IF amyloid-targeted immunotherapy is administered to patients with severe cortical atrophy (global cortical thickness <1.5mm) versus preserved cortical thickness (>2.0mm), THEN CSF p-tau217 will decline in the preserved-atrophy group by ≥30% at month 12 but show <10% change in the severe-atrophy gro
Predicted outcome: Patients with preserved cortical thickness will show ≥30% reduction in CSF p-tau217 at month 12 post-treatment, while severe-atrophy patients will sho
Falsification: Both atrophy groups show equivalent p-tau217 decline (≥30%) following amyloid reduction, indicating p-tau217 reliably reflects pathology regardless of atrophy severity and the floor effect hypothesis
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.